PubMed Health⌕ Search

Biomedical subjects

S Kurasawa

Publications and source records attributed to S Kurasawa.

20 records · Page 2Linked to original sources

Marinactan, antitumor polysaccharide produced by marine bacteria.

Extracellular polysaccharides of marine bacteria were screened for their antitumor activity against sarcoma-180 solid tumor in mice. An active polysaccharide was purified and named marinactan. The producing microorganism has a typical marine bacterial nature requiring sea water for growth and was identified as Flavobacterium uliginosum. Marinactan is a novel heteroglycan consisting of glucose, mannose and fucose in a ratio of approximately 7:2:1. Marinactan, 10-50 mg mg/kg daily for 10 days i.p., produced 70-90% inhibition of the growth of solid sarcoma 180. Complete regression of the tumor was observed in some treated mice. Its administrations before and after tumor transplantation showed almost the same inhibitory effect. Marinactan prolonged markedly the survival period of mice bearing ascites sarcoma 180.

Animals↗

[Laboratory and clinical studies on latamoxef in the field of obstetrics and gynecology].

Latamoxef (LMOX) is a new antibiotic synthesized by Shionogi Research Laboratory. Chemically LMOX is especially unique with a sulfur atom replacing the oxygen atom in the 1 position of the conventional cephalosporin nucleus, and in addition, this antibiotic has a cephamycin-like structure. The antibacterial activity of LMOX shows high potency against Gram-negative bacteria, but tends to be weak against Gram-positive bacteria. The tissue levels of LMOX in humans after intravenous injection of 1 g were examined. The levels in uterine and adnexa uteri tissue at 1 hour after administration were 25.4 and 27.4 micrograms/g respectively. LMOX was administered to 147 cases in infections of obstetric and gynecological field. The clinical effect according to disease was 94.6% for intrauterine infections, 95.0% for adnexitis, 87.0% intrapelvic infections, and 100% for external genital organ infections, making a total of 92.5%. The rate of occurrence of side effects or abnormal laboratory findings was similar to or slightly less than that seen with other beta-lactam antibiotics.

Adult↗